CoChat
Sign Up
Cited by 124Advanced Drug Delivery SystemsInhalation and Respiratory Drug DeliveryAdvancements in Transdermal Drug Delivery

The DOI matches its Crossref record; 67 of the 74 references it cites were found in a registry or an index.

Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion

Abdou, Ebtsam M., Kandil, Soha M., Miniawy, Hala M.F. El·2017·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2017.07.030
Open this paper in CoChat — free account

Abstract

Zolmitriptan (ZT) is a well-tolerated drug in migraine treatment suffering from low bioavailability due to low amount of the drug that reaches the brain after oral and nasal delivery. Development of new nasal mucoadhesive nanoemulsion formulation for zolmitriptan may success in delivering the drug directly from the nose to the brain to achieve rapid onset of action and high drug concentration in the brain which is required for treatment of acute migraine. ZT mucoadhesive nanoemulsion were prepared and characterized for drug content, zeta potential, particle size, morphology, residence time and permeation through the nasal mucosa. The selected formula was tested in-vivo in mice for its pharmacokinetics in comparison with intravenous and nasal solution of zolmitriptan. Results showed that addition of chitosan as mucoadhesive agent in 0.3% concentration to the nanoemulsion enhanced its residence time and zetapotential with no significant effect on the globule size. All tested formulations showed higher permeability coefficients than the zolmitriptan solution through the nasal mucosa. In-vivo studies showed that the mucoadhesive nanoemulsion formulation of zolmitriptan has higher AUC 0-8 and shorter T max in the brain than the intravenous or the nasal solution. This was related to the small globule size and higher permeability of the formulation.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2017.07.030

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 74 references

Research works printed but not linked: 6

  1. Awari, 2013, Bio analytical hplc method development and validation of zolmitriptan in rabbit plasma, Int. J. Bio. Pharm. Res., 4, 1160
  2. Kolsure, 2012, Development of zolmitriptan gel for nasal administration, Asian J. Pharm. Clin. Res., 5, 88
  3. Meor Mohd Affandi, 2011, Development and stability evaluation of Astaxanthin nanoemulsion, Asian J. Pharm. Clin. Res., 4, 142
  4. Niranjan, 2015, Formulation, design and in vitro evaluation of zolmitriptan immediate release tablets using Primojel and AC-Di-Sol, J. Pharm. Sci. Res., 7, 545
  5. Patel, 2013, Formulation and evaluation of microemulsion based-drug delivery system for intranasal administration of olanzapine, Int. J. Biomed. Pharm. Sci., 7, 20
  6. Tandel, 2015, Preparation and study of efavirenz microemulsion drug delivery system for enhancement of bioavailability, Euro. J. Pharm. Med. Res., 2, 1156

Cited by

Sorted by citations

See all 124

Related

Metadata

Authors
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E.
Affiliations
  • National Organization for Drug Control and Research (EG)
  • Modern University for Information and Technology (EG)
  • Cairo University (EG)
Corresponding author
Abdou, Ebtsam M.
ORCID
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2017-08
Volume
529
Issue
1-2
Pages
667-677
ISSN
0378-5173 (ISSN-L)
DOI
10.1016/j.ijpharm.2017.07.030
OpenAlex
W2735486104
Cited by
124
References
74
Citations by year
2026: 8 · 2025: 15 · 2024: 17 · 2023: 12 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 18 · 2018: 4
FWCI
5.51
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • International Journal of Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
zolmitriptan, migraine, intranasal drug delivery, chitosan, nasal mucosa permeation, brain targeting, pharmacokinetics, residence time, globule size, zeta potential, acute migraine treatment
MeSH terms
Administration, Intranasal, Animals, Brain, Chemistry, Pharmaceutical, Migraine Disorders, Nasal Mucosa, Tryptamines, Oxazolidinones, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review